scholarly journals CD44 is associated with tumor recurrence and is an independent poor prognostic factor for patients with localized clear cell renal cell carcinoma after nephrectomy

2012 ◽  
Vol 3 (5) ◽  
pp. 811-817 ◽  
Author(s):  
BYUNG-JOO JEONG ◽  
ZHE LONG LIANG ◽  
SONG MEI HUANG ◽  
JAE SUNG LIM ◽  
JIN MAN KIM ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Recurrence ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor

scholarly journals Overexpression of G6PD Represents a Potential Prognostic Factor in Clear Cell Renal Cell Carcinoma

2017 ◽  
Vol 8 (4) ◽  
pp. 665-673 ◽  
Author(s):  
Qiao Zhang ◽  
Xiaojia Yi ◽  
Zhe Yang ◽  
Qiaoqiao Han ◽  
Xuesong Di ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Potential Prognostic Factor

scholarly journals Synchronous Brain Metastases as a Poor Prognosis Factor in Clear Cell Renal Carcinoma: A Strong Argument for Systematic Brain Screening

2021 ◽  
Author(s):  
Valentine Ruste ◽  
Marie-Pierre Sunyach ◽  
Ronan Tanguy ◽  
Emmanuel Jouanneau ◽  
Camille Schiffler ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Whole Brain Radiotherapy ◽  
Progression Free Survival ◽  
Cell Renal Cell Carcinoma ◽  
Strong Argument ◽  
Poor Prognostic Factor ◽  
Fuhrman Grade

Abstract PurposeBrain metastases (BM) usually represent a poor prognostic factor in solid tumors. About 10% of patients with renal cancer (RCC) will present BM. Local therapies such as stereotactic radiotherapy (SRT), whole brain radiotherapy (WBRT), and surgery are used to achieve brain control. We compared survival between patients with synchronous BM (SynBM group) and metachronous BM (MetaBM group). MethodsIt is a retrospective study of patients with clear cell renal cell carcinoma (ccRCC) and BM treated with TKI between 2005 and 2019 at the Centre Léon Bérard in Lyon. We collected prognostic factors: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, the TNM stage, the histological subtypes and the Fuhrman grade. Overall survival (OS) was defined from diagnosis of metastatic ccRCC to death. Brain progression-free survival (B-PFS) was defined from focal brain therapy to brain progression or death.Results99 patients were analyzed, 44 in the SynBM group and 55 in the MetaBM group. OS in the MetaBM group was 49.4 months versus 19.6 months in the SynBM group, p=0.0002. The median time from diagnosis of metastasic disease to apparition of BM in the MetaBM group was 22.9 months (4.3; 125.7). SRT was used for 101 lesions (66.4%), WBRT for 25 patients (16.4%), surgery for 21 lesions (13.8%), surgery followed by radiation for 5 lesions (3.3%). B-PFS for all patients was 7 months (IC95% [5.0-10.5]). ConclusionsSurvival of patients with synchronous BM is inferior to that of patients with metachronous BM. Outcome is poor in both cases after diagnosis of BM. Brain screening should be encouraged at time of diagnosis of metastatis in ccRCC.

scholarly journals PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma

Aging ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 7585-7602 ◽  
Author(s):  
Giuseppe Stefano Netti ◽  
Giuseppe Lucarelli ◽  
Federica Spadaccino ◽  
Giuseppe Castellano ◽  
Margherita Gigante ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Tumor Microenvironment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document